1 unchanged sentence
following disclosures set forth certain information with respect to all securities sold by the Company during the three months ended
−Removed: June 30, 2023 without registration under the Securities Act:
−Removed: April 10, 2023, the Company issued an aggregate of 16,471 shares of common stock related to the cashless exercise of options held by
−Removed: Dmytry Shepsen.
+Added: September 30, 2023 without registration under the Securities Act:
+Added: July 10, 2023, July 14, 2023, August 7, 2023 and August 29, 2023, the Company issued 12,500, 25,000, 75,000 and 25,000 shares, respectively,
+Added: of common stock for services, including vested restricted stock units, to employees and consultants.
+Added: July 10, 2023, the Company issued 100,000 shares of common stock related to the settlement of the Harborside
+Added: Advisors LLC v.
+Added: 21-cv-10593, and the Specialty Medical Drugstore, LLC D/B/A GoGoMeds v.
+Added: 21-cv-10599, matters.
+Added: The shares issued were valued based on the closing price of the Company’s stock, or $5.32, on the
+Added: date of settlement, July 10, 2023.
February 4, 2023, the Company entered into the First Amendment to the Stock Purchase Agreement (the “First Amendment”) between
3 unchanged sentences
five quarterly installments beginning on or before February 6, 2023 and ending January 15, 2024.
−Removed: On April 17, 2023, the Company issued
−Removed: 455,319 shares of common stock related to the second of five quarterly installment payments due to the sellers of Cleared under the First
−Removed: May 1, 2023 and May 23, 2023, the Company issued 3,000 and 50,000 shares, respectively, of common stock for services, including vested
−Removed: restricted stock units, to employees and consultants.
+Added: On July 17, 2023, the Company issued
+Added: 158,129 shares of common stock related to the third of five quarterly installment payments due to the sellers of Cleared under the First
+Added: July 10, 2023 and August 14, 2023, PA001 Holdings, the holder of the Company’s Series B Preferred Stock elected to convert 2,275
+Added: and 1,225 shares, respectively, of the Company’s Series B Preferred Stock at a price of $3.25 per share of Series B Preferred Stock,
+Added: pursuant to the terms of the Securities Purchase Agreement dated August 28, 2020.
+Added: The conversion was calculated based on the original
+Added: issuance price of the Series B Preferred Stock plus all accrued dividends to date.
+Added: The conversion resulted in 1,010,170 and 550,694 shares
+Added: of the Company’s common stock issued to PA001 Holdings on July 12, 2023 and August 15, 2023, respectively.
+Added: The Company issued the
+Added: shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2)
+Added: of the Securities Act because of the limited number of purchasers, size of the offering, manner of the offering and number of
+Added: securities offered.
+Added: In addition, PA001 Holdings had the necessary investment intent as required by Section 4(a)(2) of the Securities
+Added: Act since PA001 Holdings agreed to, and received, the securities bearing a legend stating that such securities are restricted pursuant
+Added: to Rule 144 of the Securities Act.
+Added: This restriction ensures that these securities would not be immediately redistributed into the market
+Added: and therefore not be part of a “public offering.”
+Added: September 28, 2023, the Company issued an aggregate of 57,901 shares of common stock related to the cashless exercise of options held
+Added: by Kevin Veal, an employee of the Company, at an exercise price of $1.50 per share.
above transactions did not involve any underwriters, underwriting discounts or commissions, or any public offering.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.